Skip to main content
. 2010 Nov 25;66(2):260–264. doi: 10.1093/jac/dkq433

Table 1.

Patient characteristics and efficiency of HIV-1 genotyping from DBS in 36 individuals failing ART in rural Tanzania

ID no. Viral load (copies/mL) CD4 (cells/mm3) Subtype Current ART regimena Months since starting ART Plasma genotype DBS genotype in-house assayb DBS genotype ViroSeq assay
1 368 3000 381 D d4T, 3TC, EFV 14.6 + + +
2 477 500 19 D d4T, 3TC, NVP 32.3 + + +
3 434 100 31 C ZDV, 3TC, EVF 42.1 + + +
4 420 000 969 C d4T, 3TC, EFV 24.0 + + +
5 281 500 214 A no (d4T, 3TC, NVP) 45.9 + + −
6 229 000 371 C no (d4T, 3TC, EFV) 24.0 + + +
7 154 200 62 D no (d4T, 3TC, NVP) 16.7 + + +
8 132 000 223 D no (d4T, 3TC, NVP) 30.0 + + +
9 122 900 488 A no (d4T, 3TC, NVP) 9.7 + + −
10 120 200 469 A no (d4T, 3TC, NVP) 30.0 + + +
11 113 400 432 C ZDV, 3TC, NVP 24.5 + + +
12 81 690 673 CRF01_AE d4T, 3TC, NVP 35.5 + + +
13 76 700 224 A d4T, 3TC, NVP 9.2 + + +
14 73 400 526 A no (ZDV, 3TC, NVP) 27.3 + + +
15 44 250 547 A no (d4T, 3TC, NVP) 9.2 + + +
16 35 400 302 A d4T, 3TC, NVP 19.0 + + −
17 20 500 122 A d4T, 3TC, EFV 28.3 + + −
18 15 600 117 C d4T, 3TC, NVP 17.8 + + −
19 14 750 445 A d4T, 3TC, EFV 24.2 + + +
20 12 390 148 D no (d4T, 3TC, NVP) 30.9 + + +
21 8690 162 D d4T, 3TC, NVP 49.1 + + −
22 5990 768 D d4T, 3TC, NVP 36.9 + + +
23 5560 388 CRF01_AE no (ZDV, 3TC, NVP) 9.8 + + −
24 3965 144 D d4T, 3TC, NVP 27.3 + + −
25 3198 190 D no (ZDV, 3TC, EFV) 16.2 + + +c
26 3101 299 A d4T, 3TC, NVP 14.5 + + −
27 3000 223 C d4T, 3TC, NVP 28.3 + + −
28 2621 244 A d4T, 3TC, NVP 32.4 + − −
29 2400 271 D d4T, 3TC, NVP 31.3 + + −
30 2290 454 C d4T, 3TC, NVP 28.6 + + −
31 2260 495 C ZDV, 3TC, NVP 25.9 + + −
32 1980 635 D d4T, 3TC, NVP 26.5 + + −
33 1886 432 C d4T, 3TC, NVP 24.0 + + −
34 1504 354 D d4T, 3TC, NVP 30.4 + + −
35 1432 810 CRF01_AE d4T, 3TC, NVP 21.1 + − −
36 1349 419 C d4T, 3TC, NVP 34.7 + + −

d4T, stavudine; ZDV, zidovudine; 3TC, lamivudine; NVP, nevirapine; EFV, efavirenz.

aIn patients who discontinued ART, past treatment is shown in parentheses.

bResults by the use of an in-house assay have been published previously.7

cOnly the protease region was amplified.